

Variant: *NM_033508.3:c.817G>A*

Version: 1.1

[CA367400488](#)

[3383924 \(ClinVar\)](#)

Gene: GCK ([HGNC:2645](#))

Condition: monogenic diabetes ([MONDO:0015967](#))

Inheritance Mode: Semidominant inheritance

UUID: 1ee3be95-bcae-4658-a78b-6562fe0e8e21

Approved on: 2025-10-28

Published on: 2025-10-28

HGVS expressions

NM_033508.3:c.817G>A

NC_000007.14:g.44147693C>T
CM000669.2:g.44147693C>T
NC_000007.13:g.44187292C>T
CM000669.1:g.44187292C>T
NC_000007.12:g.44153817C>T
NG_008847.1:g.46731G>A
NG_008847.2:g.55478G>A
ENST00000395796.8:c.*818G>A
ENST00000616242.5:c.820G>A
ENST00000345378.7:c.823G>A
ENST00000403799.8:c.820G>A
ENST00000671824.1:c.820G>A
ENST00000673284.1:c.820G>A
ENST00000345378.6:c.823G>A
ENST00000395796.7:c.817G>A
ENST00000403799.7:c.820G>A
ENST00000437084.1:c.769G>A
ENST00000616242.4:c.817G>A
NM_000162.3:c.820G>A
NM_033507.1:c.823G>A
NM_033508.1:c.817G>A
NM_000162.4:c.820G>A
NM_001354800.1:c.820G>A
NM_033507.2:c.823G>A
NM_033508.2:c.817G>A
NM_000162.5:c.820G>A
NM_033507.3:c.823G>A

Likely Pathogenic

Met criteria codes **7**

PP1 PP2 PP3 PM5_Supporting
PM2_Supporting PP4_Moderate
PS4_Moderate

Evidence Links **0**

Expert Panel

[Monogenic Diabetes VCEP](#)















Criteria Specification Information

Evidence submitted by expert panel

Monogenic Diabetes VCEP

The c.820G>A variant in the glucokinase gene, GCK, is a missense variant resulting in an amino acid change of aspartic acid to asparagine at codon 274 (p.(Asp274Asn)) of NM_000162.5. This variant is absent from gnomAD v2.1.1 (PM2_Supporting). GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). Additionally, it is predicted to be deleterious by computational evidence, with a REVEL score of 0.935, which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (fasting glucose 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate; internal lab contributor). Furthermore, the variant segregated with diabetes in this family with three informative meioses (PP1, internal lab contributors). This variant was identified in four unrelated individuals with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PS4_Moderate; PMIDs: 32086287, 36257325, internal lab contributors). Another missense variant at the same amino acid, c.820G>A p.(Asp274Ala), has been classified as pathogenic by the ClinGen MDEP, but p.Asp274Asn has a smaller Grantham distance (PM5_Supporting). In summary, c.820G>A variant meets the criteria to be classified as likely pathogenic for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP VCEP (specification version 1.3.0, approved 8/11/2023): PS4_Moderate; PM2_Supporting, PP2, PP3, PP4_Moderate, PP1, PM5_Supporting.

Met criteria codes

PP1			This variant segregated with diabetes in a single family with 3 informative meioses (PP1, internal lab contributor).
PP2			GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).
PP3			This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.935, which is greater than the MDEP VCEP threshold of 0.70 (PP3).
PM5_Supporting			Another missense variant at the same amino acid, c.820G>A p.(Asp274Ala), has been classified as pathogenic by the ClinGen MDEP, but and p.Asp274Asn has a smaller Grantham distance (PM5_Supporting).
PM2_Supporting			This variant is absent from gnomAD v2.1.1 (PM2_Supporting).
PP4_Moderate			This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies) (PP4_Moderate; internal lab contributor).
PS4_Moderate			This variant was identified in four unrelated individuals with non-autoimmune and non-absolute/near-absolute insulin-deficient diabetes (PP4_Moderate; PMIDs: 32086287, 36257325, internal lab contributors).



Showing 1 to 2 of 2 rows

See Report	Preferred Variant Title	Classification ⓘ	Condition	Published Date	Version ⓘ	Criteria Specification	Gene
View	NM_033508.3:c.817G>A	Likely Pathogenic	Monogenic Diabetes ↗	2025-10-28	1.1	ClinGen Monogenic Diabetes Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for GCK Version 1.3.0 ↗	GCK ↗
View	NM_033508.3:c.817G>A	Likely Pathogenic	Monogenic Diabetes ↗	2024-11-05	1.0	ClinGen Monogenic Diabetes Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for GCK Version 1.3.0 ↗	GCK ↗

Showing 1 to 2 of 2 rows

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.